Skip to main content
Lung cancer study to report in second half of 2018
3/13/2018

AstraZeneca's late-stage trial testing Imfinzi, on its own or with tremelimumab, against lung cancer should yield results in the second half of 2018, according to the drugmaker.

Full Story: